Biohaven is a broad portfolio biopharmaceutical development company, discovering and developing innovative late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders and strategic therapeutic adjacencies.
VIDEOS
Interview with CEO Vlad Coric M.D. on CNBC’s Mad Money
Diseases related to glutamate dysregulation
We Are Biohaven